No Prescription |
 |
 | ||
|
Renitec Vasotec |
|
| ||
No Prescription » Prescription Drugs 14 » Renitec Vasotec Product Origin: EU (Turkey)This product is able to be sourced and supplied at excellent prices because of favourable cross border currency conversions. All products are authentic brand names and will include a product information insert in English.Medical Information:Renitec is indicated in the treatment of hypertension (includes combination with hydrochlorothiazide). Renitec is indicated for the treatment of symptomatic congestive heart failure usually in combination with diuretics and digitalis. Asymptomatic left ventricular dysfunction. Enalapril is in a group of drugs called ACE inhibitors. ACE stands for angiotensin converting enzyme. Enalapril is used to treat high blood pressure (hypertension) congestive heart failure kidney problems caused by diabetes and to improve survival after a heart attack. Buy Renitec Vasotec and other Prescription Drugs 14 products online at Medstore. Buy Online at Medstore - Click Here!
About Renitec Vasotec: Product Type: Prescription Drugs 14 Renitec ( Vasotec Generic Enalapril ) Renitec (Vasotec Generic Enalapril) Vasotec Generic Enalapril 10mg Vasotec Generic Enalapril Renitec
View more Prescription Drugs 14 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
